Form 4: Vanda Pharmaceuticals Director Acquires Shares

Phaedra Chrousos, a Director at Vanda Pharmaceuticals Inc., acquired 41,600 shares of common stock through a restricted stock unit award.

Summary

• Phaedra Chrousos, a Director at Vanda Pharmaceuticals Inc. (VNDA), acquired 41,600 shares of common stock on June 4, 2026.
• These shares were acquired as part of a time-based restricted stock unit (RSU) award.
• The RSU award vests fully on June 4, 2027, contingent upon continuous service to the company.
• Following this transaction, Chrousos beneficially owns 164,950 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard RSU award and vesting event for a director, with no immediate financial impact or significant strategic information.

Positives

• Director Phaedra Chrousos has acquired a significant number of shares (41,600) through an RSU award, indicating continued commitment and alignment with the company's performance.
• The vesting schedule of the RSU award (June 4, 2027) suggests a long-term incentive structure for the director.

Future Outlook

The filing does not contain forward-looking statements or guidance. The vesting of the RSU award on June 4, 2027, is a future event contingent on continued service.

Industry Context

StockSavvy.ai notes that the acquisition of shares by a director through an RSU award is a common practice in the pharmaceutical industry to align executive interests with shareholder value and incentivize long-term performance.

Stakeholder Impact

• Shareholders: The acquisition by a director through an RSU award can be seen as a positive signal of commitment, but it does not represent a new investment of personal capital.
• Employees: The RSU award structure is a common form of executive compensation, aligning management with long-term company success.

Next Steps

• Phaedra Chrousos to provide continuous service to Vanda Pharmaceuticals Inc. through June 4, 2027, for the RSU award to vest.

Key Dates

Keywords

Vanda Pharmaceuticals, VNDA, Form 4, SEC Filing, Director, Restricted Stock Unit, RSU, Share Acquisition, Beneficial Ownership